

Author Index Volume 1 (2012)

The issue number is given in front of the pagination

- A'Campo, L.E.I., N.G.A. Spliethoff-Kamminga and R.A.C. Roos, The Patient Education Program for Huntington's Disease (PEP-HD) (1) 47-56
- Alberch, J., see Giralt, A. (2) 155-173
- André, V.M., see Galvan, L. (1) 17-25
- Andrews, S., see Fisher, F. (2) 187-193
- Argyropoulos, A., see Renoir, T. (2) 261-266
- Ayton, S., see Cherny, R.A. (2) 211-219
- Biglan, K.M., E.R. Dorsey, R.V.V. Evans, C.A. Ross, S. Hersch, I. Shoulson, W. Matson and K. Kiebertz for the Huntington Study Group Pre-2CARE Investigators, Plasma 8-hydroxy-2'-deoxyguanosine Levels in Huntington Disease and Healthy Controls Treated with Coenzyme Q10 (1) 65-69
- Bissada, N., see Graham, R.K. (2) 243-260
- Bourke, D., G. Finucane, J. Dysart and R. Roxburgh, The Appointment of a Huntington's Disease Nurse Specialist has Reduced Admission Rate and Improved Admission Quality (1) 27-30
- Brooks, S., see Busse, M. (2) 175-185
- Bulley, S.J., C.J.G. Drew and A.J. Morton, Direct Visualisation of Abnormal Dendritic Spine Morphology in the Hippocampus of the R6/2 Transgenic Mouse Model of Huntington's Disease (2) 267-273
- Buonincontri, G., see Wood, N.I. (1) 57-64
- Bush, A.I., see Cherny, R.A. (2) 211-219
- Busse, M., H. Khalil, S. Brooks, L. Quinn and A. Rosser, Practice, Progress and Future Directions for Physical Therapies in Huntington's Disease (2) 175-185
- Carpenter, T.A., see Wood, N.I. (1) 57-64
- Cepeda, C., see Galvan, L. (1) 17-25
- Cherny, R.A., S. Ayton, D.I. Finkelstein, A.I. Bush, G. McColl and S.M. Massa, PBT2 Reduces Toxicity in a *C. elegans* Model of polyQ Aggregation and Extends Lifespan, Reduces Striatal Atrophy and Improves Motor Performance in the R6/2 Mouse Model of Huntington's Disease (2) 211-219
- Churchyard, A., see Fisher, F. (2) 187-193
- Clabough, E.B.D., see Neveklovskaja, M. (1) 71-87
- Coleman, A., see Dumas, E.M. (1) 97-106
- Cummings, B.J., see Sontag, E.M. (1) 119-132
- dar Santos, R.C., see Dumas, E.M. (1) 97-106
- Deng, Y., see Graham, R.K. (2) 243-260
- Díaz de Santiago, A., see López-Sendón Moreno, J.L. (1) 31-32
- Dinesh, D., see Riva. L. (1) 33-45
- Dorsey, E.R., see Biglan, K.M. (1) 65-69
- Drew, C.J.G., see Bulley, S.J. (2) 267-273
- Duennwald, M.L., see Riva. L. (1) 33-45
- Dumas, E.M., M.J. Say, R. Jones, I. Labuschagne, A.M. O'Regan, E.P. Hart, S.J.A. van den Bogaard, S. Queller, D. Justo, A. Coleman, R.C. dar Santos, A. Dürr, B.R. Leavitt, S.J. Tabrizi, R.A.C. Roos and J.C. Stout, Visual Working Memory Impairment in Premanifest Gene-Carriers and Early Huntington's Disease (1) 97-106
- Dürr, A., see Dumas, E.M. (1) 97-106
- Dysart, J., see Bourke, D. (1) 27-30
- Ehrnhoefer, D., see Graham, R.K. (2) 243-260
- Ellerby, L.M., see Sarantos, M.R. (2) 195-210
- Evans, R.V.V., see Biglan, K.M. (1) 65-69
- Fan, J., see Park, K.H.J. (1) 89-96
- Faull, R.L.M., see Waldvogel, H.J. (2) 143-153
- Fayos, J.M.P., see López-Sendón Moreno, J.L. (1) 31-32
- Finkelstein, D.I., see Cherny, R.A. (2) 211-219
- Finucane, G., see Bourke, D. (1) 27-30
- Fisher, F., S. Andrews, A. Churchyard and S. Mathers, Home or Residential Care? The Role of Behavioral and Psychosocial Factors in Determining Discharge Outcomes for Inpatients with Huntington's Disease (2) 187-193
- Fraenkel, E., see Riva. L. (1) 33-45
- Franciosi, S., see Graham, R.K. (2) 243-260
- Gabery, S., see Petersén, Å. (1) 5-16
- Galvan, L., V.M. André, E.A. Wang, C. Cepeda and M.S. Levine, Functional Differences Between

- Direct and Indirect Striatal Output Pathways in Huntington's Disease (1) 17-25
- García de Yébenes, J., see López-Sendón Moreno, J.L. (1) 31-32
- Giralt, A., A. Saavedra, J. Alberch and E. Pérez-Navarro, Cognitive Dysfunction in Huntington's Disease: Humans, Mouse Models and Molecular Mechanisms (2) 155-173
- Giussani, D.A., see Wood, N.I. (1) 57-64
- Glabe, C.G., see Sontag, E.M. (1) 119-132
- Graham, R.K., Y. Deng, M.A. Pouladi, K. Vaid, D. Ehrnhoefer, A.L. Southwell, N. Bissada, S. Franciosi and M.R. Hayden, Caspase-6-Resistant Mutant Huntingtin Does not Rescue the Toxic Effects of Caspase-Cleavable Mutant Huntingtin *in vivo* (2) 243-260
- Hannan, A.J., see Renoir, T. (2) 261-266
- Hart, E.P., see Dumas, E.M. (1) 97-106
- Hayden, M.R., see Graham, R.K. (2) 243-260
- Hayden, M.R., see Strong, M.K. (2) 221-241
- Hersch, S., see Biglan, K.M. (1) 65-69
- Hughes, R.E., see Sarantos, M.R. (2) 195-210
- Jones, R., see Dumas, E.M. (1) 97-106
- Justo, D., see Dumas, E.M. (1) 97-106
- Kane, A.D., see Wood, N.I. (1) 57-64
- Khalil, H., see Busse, M. (2) 175-185
- Kieburz, K., see Biglan, K.M. (1) 65-69
- Kim, E.H., see Waldvogel, H.J. (2) 143-153
- Koeva, M., see Riva. L. (1) 33-45
- Labuschagne, I., see Dumas, E.M. (1) 97-106
- Larkin, P.B., and P.J. Muchowski, Genetic Deficiency of Complement Component 3 does not Alter Disease Progression in a Mouse Model of Huntington's Disease (1) 107-118
- Leavitt, B.R., and L.M. Thompson, Journal of Huntington's Disease (1) 1
- Leavitt, B.R., see Dumas, E.M. (1) 97-106
- Leavitt, B.R., see Park, K.H.J. (1) 89-96
- Levine, M.S., see Galvan, L. (1) 17-25
- López-Sendón Moreno, J.L., J.M.P. Fayos, A. Díaz de Santiago and J. García de Yébenes, Neuroleptic Malignant Syndrome Induced by Olanzapine in a Patient with Huntington's Disease (1) 31-32
- Lotz, G.P., see Sontag, E.M. (1) 119-132
- Lu, G., see Park, K.H.J. (1) 89-96
- MacGregor, G.R., see Strong, M.K. (2) 221-241
- Massa, S.M., see Cherny, R.A. (2) 211-219
- Mathers, S., see Fisher, F. (2) 187-193
- Matson, W., see Biglan, K.M. (1) 65-69
- Mazor, T., see Riva. L. (1) 33-45
- McColl, G., see Cherny, R.A. (2) 211-219
- Morton, A.J., see Bulley, S.J. (2) 267-273
- Morton, A.J., see Wood, N.I. (1) 57-64
- Muchowski, P.J., see Larkin, P.B. (1) 107-118
- Muchowski, P.J., see Sontag, E.M. (1) 119-132
- Neveklovskaja, M., E.B.D. Clabough, J.S. Steffan and S.O. Zeitlin, Deletion of the Huntingtin Proline-Rich Region does not Significantly Affect Normal Huntingtin Function in Mice (1) 71-87
- Niu, Y., see Wood, N.I. (1) 57-64
- O'Regan, A.M., see Dumas, E.M. (1) 97-106
- Papanikolaou, T., see Sarantos, M.R. (2) 195-210
- Park, K.H.J., G. Lu, J. Fan, L.A. Raymond and B.R. Leavitt, Decreasing Levels of the cdk5 Activators, p25 and p35, Reduces Excitotoxicity in Striatal Neurons (1) 89-96
- Pérez-Navarro, E., see Giralt, A. (2) 155-173
- Petersén, Å., and S. Gabery, Hypothalamic and Limbic System Changes in Huntington's Disease (1) 5-16
- Pirhaji, L., see Riva. L. (1) 33-45
- Pouladi, M.A., see Graham, R.K. (2) 243-260
- Queller, S., see Dumas, E.M. (1) 97-106
- Quinn, L., see Busse, M. (2) 175-185
- Raymond, L.A., see Park, K.H.J. (1) 89-96
- Renoir, T., A. Argyropoulos and A.J. Hannan, Antidepressant-Like Effect of the Norepinephrine-Dopamine Reuptake Inhibitor Bupropion in a Mouse Model of Huntington's Disease with Dopaminergic Dysfunction (2) 261-266
- Riva. L., M. Koeva, F. Yildirim, L. Pirhaji, D. Dinesh, T. Mazor, M.L. Duennwald and E. Fraenkel, Polyglutamine Expanded Huntingtin Dramatically Alters the Genome-Wide Binding of HSF1 (1) 33-45
- Roos, R.A.C., see A'Campo, L.E.I. (1) 47-56
- Roos, R.A.C., see Dumas, E.M. (1) 97-106
- Ross, C.A., see Biglan, K.M. (1) 65-69
- Rosser, A., see Busse, M. (2) 175-185
- Roxburgh, R., see Bourke, D. (1) 27-30
- Saavedra, A., see Giralt, A. (2) 155-173
- Sarantos, M.R., T. Papanikolaou, L.M. Ellerby and R.E. Hughes, Pizotifen Activates ERK and Provides

- Neuroprotection *in vitro* and *in vivo* in Models of Huntington's Disease (2) 195-210
- Sawiak, S.J., see Wood, N.I. (1) 57-64
- Say, M.J., see Dumas, E.M. (1) 97-106
- Shoulson, I., see Biglan, K.M. (1) 65-69
- Sontag, C.J., see Sontag, E.M. (1) 119-132
- Sontag, E.M., G.P. Lotz, G. Yang, C.J. Sontag, B.J. Cummings, C.G. Glabe, P.J. Muchowski and L.M. Thompson, Detection of Mutant Huntingtin Aggregation Conformers and Modulation of SDS-Soluble Fibrillar Oligomers by Small Molecules (1) 119-132
- Southwell, A.L., see Graham, R.K. (2) 243-260
- Southwell, A.L., see Strong, M.K. (2) 221-241
- Spliethoff-Kamminga, N.G.A., see A'Campo, L.E.I. (1) 47-56
- Steffan, J.S., see Neveklovska, M. (1) 71-87
- Steward, O., see Strong, M.K. (2) 221-241
- Stout, J.C., see Dumas, E.M. (1) 97-106
- Strong, M.K., A.L. Southwell, J.M. Yonan, M.R. Hayden, G.R. MacGregor, L.M. Thompson and O. Steward, Age-Dependent Resistance to Excitotoxicity in Htt CAG140 Mice and the Effect of Strain Background (2) 221-241
- Tabrizi, S.J., see Dumas, E.M. (1) 97-106
- Thompson, L.M., see Leavitt, B.R. (1) 1
- Thompson, L.M., see Sontag, E.M. (1) 119-132
- Thompson, L.M., see Strong, M.K. (2) 221-241
- Thu, D.C.V., see Waldvogel, H.J. (2) 143-153
- Tippett, L.J., see Waldvogel, H.J. (2) 143-153
- Vaid, K., see Graham, R.K. (2) 243-260
- van den Bogaard, S.J.A., see Dumas, E.M. (1) 97-106
- Waldvogel, H.J., E.H. Kim, D.C.V. Thu, L.J. Tippett and R.L.M. Faull, New Perspectives on the Neuropathology in Huntington's Disease in the Human Brain and its Relation to Symptom Variation (2) 143-153
- Wang, E.A., see Galvan, L. (1) 17-25
- Wexler, A., Eugenics, Heredity, and Huntington's Disease: A Brief Historical Perspective (2) 139-141
- Wexler, A., Huntington's Disease – A Brief Historical Perspective (1) 3-4
- Wood, N.I., S.J. Sawiak, G. Buonincontri, Y. Niu, A.D. Kane, T.A. Carpenter, D.A. Giussani and A.J. Morton, Direct Evidence of Progressive Cardiac Dysfunction in a Transgenic Mouse Model of Huntington's Disease (1) 57-64
- Yang, G., see Sontag, E.M. (1) 119-132
- Yildirim, F., see Riva. L. (1) 33-45
- Yonan, J.M., see Strong, M.K. (2) 221-241
- Zeitlin, S.O., see Neveklovska, M. (1) 71-87